A new report from the Government Accountability Office finds a slowdown in new drugs coming to market. One culprit? Abusive patent practices, says the GAO.
Big Pharma may be spending big money on drug research, but it’s not getting big breakthroughs. That’s the assessment of a report released in December by the Government Accountability Office that blames patents, among other things, for why innovative new drugs aren’t coming to market.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
